And as I said, we have some, but we’ve not typically been as focused on that. Having said that, we have done quite a bit of reimbursement work. It’s been an economic challenge for ambulatory surgery centers predominantly. We’ve done a lot of reimbursement work to make sure that there is a new structure where they can economically have it make sense for them to do nerve repair in these freestanding centers. And so under the new coding and payment structure that CMS has set up, it is now economically viable and certainly an attractive overall health care alternative to move these procedures into these ambulatory surgery centers. And we are starting to see some of that migration happen. It has been a migration, not a revolution. But we see — quarter-over-quarter, we continue to see growth of the procedures that are done in these ambulatory surgery centers, and we do expect for the future that, that will continue.
Ross Osborn: Great. That’s very helpful. And then lastly for us. Would you just walk through how your conversations have gone with accounts, sort of Avive Soft Tissue, maybe relative to the year?
Karen Zaderej: Sure. Well, we’ve done a limited market release, so it’s not broadly available. But with some leading surgeons who are very anxious to get this product back into their treatment algorithm, we’ve provided it upfront. Feedback that we’ve gotten to date has been extremely positive. Surgeons are very happy to have this alternative for nerve protection. Again, meeting the need where there’s a short-term resorbable protection need predominantly in acute trauma, although also sometimes in pain, surgical treatment of pain. And so we are excited to have this as an opportunity to provide them this added solution in their nerve treatment. Surgeon feedback has been very favorable, in fact, more positive. If you remember, we had a product called the Avive that we voluntarily withdrew from the market a number of years ago because of changes the FDA did in regulatory classifications of birth tissue products and ultimately decided that we would withdraw that product.
Surgeons liked that product. They like this product better in terms of the handling and the characteristics of the product that they’re using intraoperatively. And so we are really pleased to get it out there and excited to get in the hands of all of our sales reps and our customers to be able to use on these patients.
Operator: Thank you. And there are no further questions at this time, so I would like to turn the floor back over to Karen Zaderej for any closing comments.
Karen Zaderej: Well, thank you, Keith. Well, as we wrap up today’s earnings call, I want to extend a thank you to our team here at AxoGen for their outstanding work and to everyone who participated on this call for their engagement and input. The commitment of our employees has been crucial in reaching the achievement we’ve talked about today as we continue to change the lives of patients with peripheral nerve injuries. Thank you.
Operator: Thank you. This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.
